Esophageal Cancer Drugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan, Trifluridine and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and 5-fluorouracil, and Cisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumab and Ramuciruma

Esophageal Cancer Drugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan, Trifluridine and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and 5-fluorouracil, and Cisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumab and Ramucirumab), and Immunotherapy (Pembrolizumab)), By Disease Indication (Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous Cell Carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Esophageal cancer occurs in the cells that line the inside of the esophagus. Major symptoms include difficulty in swallowing (dysphagia), unintentional weight loss, chest pain, worsening indigestion or heartburn, coughing or hoarseness. Drugs approved by the Food and Drug Administration (FDA) such as Docetaxel, Trifluridine, and Tipiracil Hydrochloride are extensively used chemotherapy for treatment of esophageal cancer. Immunotherapy drug named Pembrolizumab is also used for the treatment of esophageal cancer. In 2017, FDA granted accelerated approval to pembrolizumab (Keytruda) for patients suffering from recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma.
Market Dynamics
Increasing prevalence of esophageal cancer worldwide is expected to boost esophageal cancer drugs market growth. According to World Cancer Research Fund (WCRF) International 2021, esophageal cancer is the seventh most commonly occurring cancer in men and the 13th most commonly occurring cancer in women. There were over 500,000 new cases in 2021, globally. Moreover, geriatric population is at high risk of developing esophageal cancer and men are more vulnerable to developing esophageal cancer. For instance, according to a data published in American Society of Clinical Oncology (ASCO) in 2021, it is estimated that people between the ages of 45 and 70 have the highest risk of esophageal cancer.
However, no drug therapy has been used to cure esophageal cancer completely and the survival rates of esophageal cancer patient significantly decreases after 5 years of treatment. The esophageal cancer drugs do not have any reliability after 5 years of treatment, which is expected to hamper growth of the esophageal cancer drugs market. For instance, according to the study published in the ASCO in January 2019, the 5-year survival rate of people with esophageal cancer is 19%.
Key features of the study:
This report provides in-depth analysis of the esophageal cancer drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global esophageal cancer drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global esophageal cancer drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global Esophageal Cancer Drugs Market, By Therapy Type:
Chemotherapy
Docetaxel
Irinotecan
Trifluridine and Tipiracil
Carboplatin and Paclitaxel
Cisplatin and 5-fluorouracil
Cisplatin with Capecitabine
Targeted Drug Therapy
Trastuzumab
Ramucirumab
Immunotherapy
Pembrolizumab
Global Esophageal Cancer Drugs Market, By Disease Indication:
Adenocarcinomas
Gastrointestinal Stromal Tumors
Carcinoid Tumors
Squamous Cell Carcinoma
Others
Global Esophageal Cancer Drugs Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Esophageal Cancer Drugs Market, By Region:
North America
By Country:
U.S.
Canada
By Therapy Type:
Chemotherapy
Docetaxel
Irinotecan
Trifluridine and Tipiracil
Carboplatin and Paclitaxel
Cisplatin and 5-fluorouracil
Cisplatin with Capecitabine
Targeted Drug Therapy
Trastuzumab
Ramucirumab
Immunotherapy
Pembrolizumab
By Disease Indication:
Adenocarcinomas
Gastrointestinal Stromal Tumors
Carcinoid Tumors
Squamous Cell Carcinoma
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Therapy Type:
Chemotherapy
Docetaxel
Irinotecan
Trifluridine and Tipiracil
Carboplatin and Paclitaxel
Cisplatin and 5-fluorouracil
Cisplatin with Capecitabine
Targeted Drug Therapy
Trastuzumab
Ramucirumab
Immunotherapy
Pembrolizumab
By Disease Indication:
Adenocarcinomas
Gastrointestinal Stromal Tumors
Carcinoid Tumors
Squamous Cell Carcinoma
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Therapy Type:
Chemotherapy
Docetaxel
Irinotecan
Trifluridine and Tipiracil
Carboplatin and Paclitaxel
Cisplatin and 5-fluorouracil
Cisplatin with Capecitabine
Targeted Drug Therapy
Trastuzumab
Ramucirumab
Immunotherapy
Pembrolizumab
By Disease Indication:
Adenocarcinomas
Gastrointestinal Stromal Tumors
Carcinoid Tumors
Squamous Cell Carcinoma
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Therapy Type:
Chemotherapy
Docetaxel
Irinotecan
Trifluridine and Tipiracil
Carboplatin and Paclitaxel
Cisplatin and 5-fluorouracil
Cisplatin with Capecitabine
Targeted Drug Therapy
Trastuzumab
Ramucirumab
Immunotherapy
Pembrolizumab
By Disease Indication:
Adenocarcinomas
Gastrointestinal Stromal Tumors
Carcinoid Tumors
Squamous Cell Carcinoma
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Therapy Type:
Chemotherapy
Docetaxel
Irinotecan
Trifluridine and Tipiracil
Carboplatin and Paclitaxel
Cisplatin and 5-fluorouracil
Cisplatin with Capecitabine
Targeted Drug Therapy
Trastuzumab
Ramucirumab
Immunotherapy
Pembrolizumab
By Disease Indication:
Adenocarcinomas
Gastrointestinal Stromal Tumors
Carcinoid Tumors
Squamous Cell Carcinoma
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Therapy Type:
Chemotherapy
Docetaxel
Irinotecan
Trifluridine and Tipiracil
Carboplatin and Paclitaxel
Cisplatin and 5-fluorouracil
Cisplatin with Capecitabine
Targeted Drug Therapy
Trastuzumab
Ramucirumab
Immunotherapy
Pembrolizumab
By Disease Indication:
Adenocarcinomas
Gastrointestinal Stromal Tumors
Carcinoid Tumors
Squamous Cell Carcinoma
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Company Profiles
Amgen Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Eli Lilly and Company
F. Hoffmann-La Roche
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
Bristol-Myers Squibb
GlaxoSmithKline Plc.
Novartis AG
Johnson & Johnson
Gilead Sciences
Genentech Inc.
Sanofi-Aventis
Merck & Co.
“*” marked represents similar segmentation in other categories in the respective section.